China NMPA Product Recall - Insulin pump infusion tubing and needle

The National Medical Products Administration (NMPA) issued a document in September 2013, detailing a voluntary recall initiated by Medtronic MiniMed and Unomedical a/s, with Medtronic (Shanghai) Management Co., Ltd. as the responsible unit in China. The recall pertains to several models of insulin pump infusion tubing and needles, which were originally imported under CFDA (China Food and Drug Administration) licenses, with over 2 million units imported to China since 1998. The primary issue identified is a potential safety concern arising when insulin or other liquids come into contact with the internal components of the infusion line connector. This can occur, for instance, if insulin spills onto the reservoir during removal from the pipette cap. Such liquid contact has been found to temporarily block the connector's vent, impeding proper pump filling. This malfunction can lead to either over-infusion or under-infusion of insulin, posing a serious health risk of hypoglycemia or hyperglycemia for users. In response to this significant safety finding, Medtronic MiniMed and Unomedical a/s are voluntarily recalling the affected products globally. The required actions include informing both individual users and healthcare professionals in hospitals about the incident, explaining the mechanism of temporary vent blockage, and providing clear corrective action instructions to prevent liquid contact and subsequent blockage. These instructions are to be incorporated as an addendum to the product manuals. Additionally, provincial, autonomous region, and municipal food and drug administrations were tasked by the NMPA to intensify their supervision of these recalled medical devices.